On April 16, Lilly announced that it was requesting FDA to revoke the emergency use authorization (EUA) for the monoclonal antibody bamlanivimab (LY-CoV555) when used alone. Hours after, the agency agreed to rescind the EUA on the grounds that bamlanivimab is potentially ineffective against some SARS-CoV-2 variants. Bamlanivimab, however, won’t be disappearing as a COVID-19…
AbCellera sees its revenue jump 1,908% in 2020
Biotech firm AbCellera (NASDAQ:ABCL) announced its full-year 2020 business results, which were dramatically higher than the previous year. The company pulled in $233 million in total revenue last year compared with $11.6 million in 2019. Net earnings for 2020 were $119 million compared to a $2 million loss in 2019. “AbCellera had a breakthrough year,…
Lilly and UnitedHealth team up on bamlanivimab study for COVID-19
Eli Lilly (NYSE:LLY) and UnitedHealth Group (NYSE:UNH) are partnering on a pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19 infections. Lilly recently won emergency use authorization from the FDA to use the monoclonal antibody bamlanivimab to treat mild to moderate COVID-19 infections in patients at risk of severe infections. The study will evaluate the…
NIAID halts Lilly COVID-19 antibody study
An arm of NIH has ended a clinical trial investigating the use of Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab) to treat hospitalized COVID-19 patients. In separate news, HHS plans to allocate 300,000 doses of the monoclonal antibody immediately, according to an announcement. While the drug shows promise in treating mild-to-moderate COVID-19 infections, the ACTIV-3 trial…